BR112013018751A2 - método de cultura de célula animal - Google Patents

método de cultura de célula animal

Info

Publication number
BR112013018751A2
BR112013018751A2 BR112013018751A BR112013018751A BR112013018751A2 BR 112013018751 A2 BR112013018751 A2 BR 112013018751A2 BR 112013018751 A BR112013018751 A BR 112013018751A BR 112013018751 A BR112013018751 A BR 112013018751A BR 112013018751 A2 BR112013018751 A2 BR 112013018751A2
Authority
BR
Brazil
Prior art keywords
animal cell
culture
protein
cell culture
culture method
Prior art date
Application number
BR112013018751A
Other languages
English (en)
Other versions
BR112013018751B1 (pt
Inventor
Shiniya Takuma
Shohei Kishishita
Tomoko Okui
Yasuharu Shinoda
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BR112013018751A2 publication Critical patent/BR112013018751A2/pt
Publication of BR112013018751B1 publication Critical patent/BR112013018751B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Abstract

método de cultura de célula animal a presente invenção refere-se a um proteína desejada que é preparada cultivando-se uma célula animal que produz a proteína para fazer com que a proteína seja produzida, o nível de componentes de homogeneidade da proteína é modulado realizando-se a cultura em uma temperatura de cultura normal durante certo período de tempo e em seguida continuando a cultura em uma temperatura de cultura reduzida de 25 a 35º c.
BR112013018751-4A 2010-12-28 2011-12-28 método para modular o nível de componentes de homogeneidade de uma proteína, método para produzir uma proteína desejada, medicamento e método para preparação do mesmo BR112013018751B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010-291636 2010-12-28
JP2010291636 2010-12-28
PCT/JP2011/080478 WO2012091124A1 (ja) 2010-12-28 2011-12-28 動物細胞の培養方法

Publications (2)

Publication Number Publication Date
BR112013018751A2 true BR112013018751A2 (pt) 2016-08-09
BR112013018751B1 BR112013018751B1 (pt) 2021-01-05

Family

ID=46383211

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013018751-4A BR112013018751B1 (pt) 2010-12-28 2011-12-28 método para modular o nível de componentes de homogeneidade de uma proteína, método para produzir uma proteína desejada, medicamento e método para preparação do mesmo

Country Status (17)

Country Link
US (1) US20130295613A1 (pt)
EP (1) EP2660328A4 (pt)
JP (1) JP6001456B2 (pt)
KR (1) KR101903208B1 (pt)
CN (2) CN103282509A (pt)
AU (1) AU2011350456B2 (pt)
BR (1) BR112013018751B1 (pt)
CA (1) CA2822947A1 (pt)
HK (1) HK1248242A1 (pt)
IL (1) IL227185B (pt)
MX (1) MX345399B (pt)
MY (1) MY163081A (pt)
NZ (1) NZ611862A (pt)
RU (1) RU2615448C2 (pt)
SG (1) SG191371A1 (pt)
WO (1) WO2012091124A1 (pt)
ZA (1) ZA201304332B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
ES2738593T3 (es) * 2012-12-10 2020-01-23 Seikagaku Kogyo Co Ltd Factor C recombinante novedoso y método para producir el mismo, y método para medir endotoxina
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN103255238A (zh) * 2013-05-15 2013-08-21 江苏泰康生物医药有限公司 一种控制哺乳动物细胞乳酸生成的方法
BR112015032800A2 (pt) * 2013-07-06 2017-07-25 Cadila Healthcare Ltd “processo para a produção de um anticorpo”
AU2014337263B2 (en) 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
CN105777896B (zh) * 2015-03-19 2019-08-16 广东东阳光药业有限公司 一种抗体酸性峰的纯化方法
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR101789509B1 (ko) * 2015-11-05 2017-10-26 주식회사 프로젠 재조합 인간 갑상선 자극 호르몬을 포함하는 조성물 및 상기 재조합 인간 갑상선 자극 호르몬의 생산 방법
CA3010600A1 (en) * 2016-01-06 2017-07-13 Oncobiologics, Inc. Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
WO2018178063A1 (en) * 2017-03-31 2018-10-04 Boehringer Ingelheim International Gmbh Perfusion medium
CN108823267B (zh) * 2018-06-25 2020-05-08 深圳市菲鹏生物制药股份有限公司 调节cho-k1表达系统所分泌抗体的酸性峰含量的方法
KR20230051921A (ko) * 2021-10-12 2023-04-19 프레스티지바이오로직스 주식회사 항체 집단의 제조 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91778A (en) * 1988-09-28 1994-10-07 Lilly Co Eli A method for reducing the heterogeneity of monoclonal antibodies
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
TW426733B (en) * 1995-10-06 2001-03-21 Merck & Co Inc Method of disrupting cultured cells using an impinging jet device
PL376821A1 (pl) * 2002-03-27 2006-01-09 Immunex Corporation Sposoby zwiększania produkcji polipeptydów
CA2491692C (en) * 2002-07-08 2010-12-07 Amersham Biosciences Uk Limited Reagents and a method for saturation labelling of proteins
NZ579543A (en) * 2004-07-09 2011-07-29 Chugai Pharmaceutical Co Ltd Anti-glypican 3 antibody
CN101541950A (zh) * 2006-07-13 2009-09-23 惠氏公司 糖蛋白的产生
DK2115126T3 (en) 2007-03-02 2015-05-04 Wyeth Llc Use of copper and glutamate in cell culture for the preparation of polypeptides
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US8680247B2 (en) * 2007-07-17 2014-03-25 Medarex, L.L.C. Monoclonal antibodies against glypican-3
CN101802192A (zh) * 2007-10-15 2010-08-11 中外制药株式会社 抗体的制备方法
RU2531521C2 (ru) * 2007-12-05 2014-10-20 Чугаи Сейяку Кабусики Кайся Антитело против nr10 и его применение
MY169935A (en) * 2011-04-29 2019-06-18 Biocon Biologics India Ltd "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof"

Also Published As

Publication number Publication date
MX345399B (es) 2017-01-30
US20130295613A1 (en) 2013-11-07
MX2013007650A (es) 2013-08-01
BR112013018751B1 (pt) 2021-01-05
KR101903208B1 (ko) 2018-10-01
CA2822947A1 (en) 2012-07-05
AU2011350456A1 (en) 2013-07-04
EP2660328A1 (en) 2013-11-06
NZ611862A (en) 2015-05-29
JPWO2012091124A1 (ja) 2014-06-05
CN107629124A (zh) 2018-01-26
CN103282509A (zh) 2013-09-04
JP6001456B2 (ja) 2016-10-05
RU2615448C2 (ru) 2017-04-04
HK1248242A1 (zh) 2018-10-12
SG191371A1 (en) 2013-08-30
KR20130131415A (ko) 2013-12-03
WO2012091124A1 (ja) 2012-07-05
EP2660328A4 (en) 2016-07-13
ZA201304332B (en) 2014-08-27
MY163081A (en) 2017-08-15
IL227185B (en) 2018-05-31
AU2011350456B2 (en) 2016-05-26
RU2013135255A (ru) 2015-02-10

Similar Documents

Publication Publication Date Title
BR112013018751A2 (pt) método de cultura de célula animal
AR087956A1 (es) METODOS Y COMPOSICIONES QUE MODULAN ACETIL-CoA CARBOXILASA PARA EL CONTROL DE MALEZAS
CL2013000143A1 (es) Granulo herbicida estable que contiene un ingrediente herbicida activo seleccionado de inhibidores de la enzima accase o als; metodo para controlar la vegetacion indeseable en un ambiente acuatico.
UY34333A (es) ?métodos y composiciones para el control de malezas, y métodos para reducir la expresión de enzima dhps?
BR112017007770A2 (pt) cultura in vitro, população de hipscs, método para modificar um locus-alvo genômico, e, hipsc.
EA201201648A1 (ru) Стимуляторы sgc
BRPI1100666A2 (pt) Método para produzir um l-aminoácido
BR112016012870A8 (pt) composições e métodos para melhorar a produção de alface
BRPI1011617A2 (pt) composição, e, métodos para aprimorar a eficácia de um regulador de crescimento de planta, e para regular crescimento de planta
MX342287B (es) Moduladores heterociclicos de sintesis lipidica.
ATE460496T1 (de) Verfahren zur herstellung von l-aminosäure
EA201301102A1 (ru) Композиция для регуляции роста растений
AR093310A1 (es) Composiciones y metodos para mejorar el crecimiento de las plantas
BR112014010448A2 (pt) microorganismos e métodos para a produção de caprolactona
BR112015020904A2 (pt) microrganismos e métodos para produção de butadieno e compostos relacionados por assimilação de formiato
BR112016016539A2 (pt) micro-organismos recombinantes enriquecidos com carboidratos
BR112012029985A2 (pt) métodos de determinação de rotatividade beta-amiloide no sangue.
EA201490024A1 (ru) Наполненные силиконовые композиции, их получение и применение
BR102013030997B8 (pt) Método para controlar conogethes punctiferalis pelo uso de uma célula vegetal transgênica que expressa a proteína cry1a
BR112013028486A2 (pt) método para promover crescimento de planta
BR112013018298A2 (pt) compostos para a redução da produção de beta-amiloides
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
BR102013031734B8 (pt) Método para controlar athetis lepigone
CL2012002411A1 (es) Composicion para controlar enfermedades vegetales que comprende un compuesto derivado de amida y uno o mas compuestos fungicidas de carboxamida; metodo para controlar enfermedades vegetales .
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/12/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2703 DE 25-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.